MaaT Pharma
Created in 2014
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
12,255Activities
Technologies
Entity types
Location
70 Av. Tony Garnier, 69007 Lyon, France
Lyon
France
Employees
Scale: 51-200
Estimated: 75
SIREN
808370100Engaged corporates
24
8 20Added in Motherbase
4 years, 6 months ago
biotech Value proposition
We restore microbiome function to treat life-threatening diseases
MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.
Hervé Affagard, CEO & Co-founder
Microbiome, Microbiota, Microbiology, MicroBiotech, pharma, GvHD, Leukemia, Dysbiosis, Symbiosis, Biotech, oncology, cancer, and gut microbiotaOriginal language
We restore microbiome function to treat life-threatening diseases
MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.
Hervé Affagard, CEO & Co-founder
MaaT Pharma - Building a leading microbiome company in oncology
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
https://www.maatpharma.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Direction Générale des Entreprises National and local authorities, Government Administration | Direction Générale des Entreprises National and local authorities, Government Administration | Other 29 Mar 2024 | | |
 France Travail Human ressources, Government Administration | France Travail Human ressources, Government Administration | Other 21 Dec 2023 | | |
 | Gouvernement | Other 29 Mar 2024 | | |
 BNP Paribas Bank, Banking | BNP Paribas Bank, Banking | Other 21 Oct 2023 | | |
 CNRS Innovation Research, Research Services | CNRS Innovation Research, Research Services | Other 29 Jun 2023 | | |
 Institut du Cerveau – Paris Brain Institute Startup accelerator & VC, Biotechnology Research | Institut du Cerveau – Paris Brain Institute Startup accelerator & VC, Biotechnology Research | Other 26 Jun 2023 | | |
 Wolters Kluwer IT services, Information Services | Wolters Kluwer IT services, Information Services | Other 5 Mar 2023 | | |
 Sofinnova Partners Financial Services | Sofinnova Partners Financial Services | Other 7 Nov 2022 | | |
 La French Tech Saint-Etienne Lyon French Tech, IT Services and IT Consulting | La French Tech Saint-Etienne Lyon French Tech, IT Services and IT Consulting | Other 7 Oct 2022 | | |
 La Tribune Media, Newspapers | La Tribune Media, Newspapers | Other 29 Oct 2023 | | |